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Abstract 
Formenti et al. have recently reported the clinical outcomes and translational 
readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with 
palliative radiotherapy in 39 patients with non-small cell lung cancer. A radiological 
response was seen in 18% of patients and 31% of patients experienced disease 
control. These clinical outcomes appear to be superior to historical studies using 
ipilimumab alone and suggest that radiation may have triggered systemic, so-called 
abscopal, immune responses in some patients. Induction of interferon-beta (IFN-β) 
and maximal expansion and contraction of distinct T cell receptor clones were the 
most significant factors predicting response. Importantly, established predictive 
biomarkers of response to immunotherapy alone, including the expression of PD-L1 
in diagnostic biopsies and tumour mutational burden, did not predict response. The 
report provides important human qualification of pre-clinical mechanistic insights 
indicating that abscopal responses can be generated with optimised radiotherapy 
fractionation schedules and anti-CTLA-4 inhibition. Additionally, an intriguing 
mechanism by which radiation can be immunogenic is described, namely radiation-
induced transcriptional upregulation of neo-antigens. 
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Main text 
Tumour shrinkage at a distance from radiotherapy portals, in the form of the 
abscopal response, has, historically, been rarely observed. The discovery of immune 
checkpoint inhibitors (ICI) has raised the possibility that abscopal responses could 
be induced more commonly by combining radiation with ICI. Formenti and 
colleagues have recently reported clinical outcomes and translational readouts from 
a trial that seeks to address this question using anti-CTLA-4 immunotherapy and 
palliative radiation in patients with non-small cell lung cancer (NSCLC) (1). Thirty-
nine patients with metastatic NSCLC received four cycles of ipilimumab with 
radiotherapy administered between days one and five of the first ipilimumab 
treatment. Recruited patients had progressed through at least one previous systemic 
treatment and had a substantial burden of metastatic disease; 41% of patients had 
pre-existing brain metastases. Over a decade of pre-clinical experimentation by the 
authors provided a sound scientific basis for the chosen fractionation schedules of 3 
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x 9.5 Gy delivered over three days and 5 x 6 Gy delivered over five days. Both 
schedules closely mirror those showing maximal synergy with anti-CTLA-4 
immunotherapy in murine models (2) although no human studies have been 
undertaken to establish these schedules as optimal in combination with 
immunotherapy in the clinic.  
 
Twenty-one of 39 patients completed all four cycles of ipilimumab and could be 
evaluated for response by RECIST criteria on day 88 following commencement of 
ipilimumab. Unfortunately, eighteen patients could not be evaluated at day 88, 
predominantly due to either disease progression or death beforehand. Of the 
evaluable patients, 7/21 (33%) showed a radiological response and a further five 
patients showed stable disease – representing a disease control rate of 12/39 (31%) 
of all patients. The median overall survival in patients with disease control was 20.4 
months (95% CI: 12.9 months to not reached) compared with 3.5 months (95% CI: 
3.1–7.4 months) in patients who did not achieve disease control (log-rank test P < 
0.001). The authors noted that radiotherapy did not add additional toxicity beyond 
that associated with ipilimumab alone. 
 
Rigorous evaluation of the abscopal effect when using immunotherapy/radiotherapy 
combinations requires randomisation of patients to immunotherapy alone versus 
radiotherapy and immunotherapy given together. Therefore, in the current non-
randomised study, it is impossible to know how much of the observed benefit was 
due to ipilimumab alone and how much was contributed by a radiation-induced 
abscopal effect. Nonetheless, the favourable clinical responses seen in the current 
study can be compared with the disappointing historical studies of CTLA-4 inhibitors, 
both as single-agents and combined with chemotherapy, in metastatic non-small cell 
lung cancer (3, 4). A recent systematic review and meta-analysis of immunotherapy 
in NSCLC found no statistically significant improvement in overall survival for anti-
CTLA-4 inhibitors (5). In the light of these poor responses, the rate of disease control 
of 31% seen by Formenti et al. suggests that a radiation-induced abscopal effect 
may be occurring in some patients.  
 
An impressive range of biological profiling using both tumour tissue and blood 
samples was conducted alongside the clinical trial, and these findings are particularly 
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interesting. Neither PD-L1 expression, an established predictive marker of response 
to immunotherapy in NSCLC (6), nor CD8+ T cell infiltration in pre-treatment 
diagnostic biopsies showed any association with treatment response. Instead, 
analysis of circulating soluble markers and immune cells at baseline indicated that 
the absolute lymphocyte count was lower and the regulatory T cell count was higher 
in responding patients versus those with stable or progressive disease. 
 
Longitudinal analysis involved evaluation of changes in immune cells and serum 
markers occurring between baseline and day 22 of treatment, i.e. shortly after 
radiotherapy completion. Two known pharmacodynamic markers for anti-CTLA-4 
response, namely ICOS expression on CD4 T cells and proliferation of CD8 and 
CD4 T cells, increased across the majority of patients irrespective of response. Other 
soluble circulating markers evaluated included major histocompatibility complex 
class I chain-related proteins A and B (sMICA/sMICB), neither of which showed any 
association with therapeutic benefit at baseline or longitudinally. 
 
In a pattern that closely mirrors findings in pre-clinical murine models, there was a 
strong association between change in serum IFN-β (between baseline and day 22 of 
treatment) and clinical response. The seven patients with a radiological response 
showed the largest rise in IFN-β. In contrast, the 23 evaluable patients with 
progressive disease (including those who did not complete ipilimumab treatment) 
showed no significant rise in IFN-β at day 22 of treatment. An intermediate rise in 
IFN-β occurred in patients with stable disease. Random forest classification identified 
change in IFN-β as the most significant predictor of response of all biological 
parameters analysed. According to the pre-clinical models, such IFN-β is produced 
following radiation-induced entry of double-stranded DNA into the cytosol and 
subsequent activation of the cGAS/STING pathway. IFN-β may be produced as both 
a tumour-cell intrinsic response or from antigen presenting cells such as BATF3-
dependent dendritic cells (7, 8).  
 
Deep sequencing of the T cell receptor (TCR) CDR3 region (TCR Seq) in peripheral 
blood samples led to identification of a second biological parameter that significantly 
predicted clinical response. Intriguingly, a specific TCR dynamic was seen whereby 
responders showed a significantly larger increase in both the expansion and 
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contraction of different TCR clones than non-responders. To investigate the tumour 
specificity of these TCR clonal dynamics seen in the blood, the authors then 
explored the TCR Seq profile of tumour-infiltrating lymphocytes (TIL-TCR) from four 
patients who showed a varied response to radiation plus ipilimumab. Sequencing of 
TIL-TCR showed that the number of tumour-specific clones expanding and persisting 
in the blood was substantially higher in the patient showing complete response than 
in the three other patients with either a less marked clinical response or disease 
progression.   
 
The selection of four patients with varied clinical response for comprehensive tumour 
profiling is likely to relate to the size of residual tumour samples. Diagnostic biopsies 
of lung tumours are often very small meaning that molecular profiling can be 
challenging. Despite this, the authors were able to perform whole exome sequencing 
(WES) alongside the TIL-TCR sequencing described earlier. WES demonstrated a 
varied mutational load across the four samples. However, neither mutational load nor 
predicted number of neo-antigens showed any correlation with clinical response. 
Additionally, the predicted MHC-I binding affinity did not differ significantly between 
predicted neo-epitopes. Finally, no specific mutations were identified in the 
frequently mutated TAP or B2M genes or in genes in the interferon pathway. In 
summary, WES did not identify predictors of clinical response, which, once again, is 
in contrast to established findings using ICI without radiotherapy (9). 
 
Next, the authors further explored the relationship between neo-epitopes and TIL-
TCR Seq and uncovered a fascinating novel mechanism of radiation-induced 
immunogenicity. Two neo-epitopes that occurred in the patient with complete 
response were both derived from the same single mutation but bound to different 
HLA loci. The mutation lies in the KPNA2 gene, which the authors demonstrated was 
upregulated by radiotherapy in a patient-derived lung cancer xenograft. TCR clones 
reacting to this mutation were almost entirely absent before radiation but showed a 
dramatic expansion in peripheral blood samples after radiation.  
 
Radiation-induced cell lysis can release existing intracellular neoantigens and 
radiation can induce new mutations via direct damage to DNA. This work 
demonstrates a third distinct mechanism by which radiation can be immunogenic, 
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namely radiation-induced upregulation of pre-existing neo-antigens. To our 
knowledge, this upregulation of neo-antigens by radiotherapy that triggers new 
tumour-specific TCR clones has not been demonstrated previously. Recent pre-
clinical studies have shown that radiotherapy causes a broadening of the TCR 
repertoire (10), which may be important for the observed synergy with ICI. As 
radiotherapy is known to cause extensive transcriptional upregulation, it is possible 
that unmasking of pre-existing neo-antigens occurs with this upregulation, which 
contributes to the broadening of the TCR repertoire described above. The precise 
impact of radiotherapy on the induction and upregulation of neo-antigens is an area 
in need of further study – including longitudinal genomic and proteomic profiling in a 
human context. 
 
There are many unanswered questions about the abscopal effect, which remains a 
somewhat elusive phenomenon. For example, is irradiation of the primary tumour, as 
opposed to metastatic sites, necessary? Does radiation need to be directed to 
lesions above a threshold size? Additionally, should the regional draining lymph 
nodes be included in or excluded from the radiation field? A number of randomised 
clinical trials currently seek to address these questions. In the meantime, this 
fascinating report indicates the potential for meaningful abscopal responses with 
ipilimumab and radiotherapy despite the considerable intra-tumoural heterogeneity of 
metastatic lung cancer. The study also reinforces the importance of embedding high 
quality translational science within clinical trials. Here, Formenti and colleagues 
provide elegant validation of pre-clinical insights about the importance of type 1 
interferon induction in a human context. Finally, there is widespread transcriptional 
upregulation in response to radiotherapy and it will be exciting to explore further how 
radiation can upregulate neo-antigens in future studies.    
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